— Know what they know.
Not Investment Advice

DSGN NASDAQ

Design Therapeutics, Inc.
1W: -4.2% 1M: -14.0% 3M: -11.6% YTD: +16.8% 1Y: +85.5% 3Y: +394.4% 5Y: -23.6%
$10.63
+0.29 (+2.80%)
Pre-Market: $11.52 (+0.89, +8.37%)
Weekly Expected Move ±8.7%
$8 $9 $10 $11 $12
NASDAQ · Healthcare · Biotechnology · Tech Score Sell · Power 30 · $665.2M mcap · 35M float · 1.95% daily turnover · Short 59% of daily vol
Credit Risk of going bust: lower than 75% of companies Debt: 0.3% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the safest four tenths, about 1 in 3,500 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.00 (down more than 99.9%), Design Therapeutics, Inc. would be worth roughly what it owes.
Total debt $2.0M against a stock market value of $665.2M.
Distance to default 8.50 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $1.0M (short-term plus half of long-term), stock volatility 73.8%; Altman Z'' 14.75. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
No news data available for DSGN

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms